Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologyViva Health Cinqair (reslizumab) Coverage | Prior …
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-P0273

    Cinqair (reslizumab) IV — coverage and prior authorization criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-P0273 alerts

    Get alerted when Policy IC-P0273 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage and prior authorization criteria for intravenous reslizumab (Cinqair) for members of Viva Health, including initial and renewal requirements, dosing limits, contraindicated concomitant therapies, and billing information.

    Policy Summary
    PayerViva Health
    PolicyCinqair (reslizumab) IV — coverage and prior authorization criteria
    Policy CodePolicy IC-P0273
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization; initial and renewals are valid for 12 months.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsPA validity
    400Max HCPCS units/4w
    3 mg/kg q4wDose (severe asthma)
    J2786HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    59310-0610-xx
    NDC
    5Covered ICD-10 codes

    Coverage and Medical Necessity Criteria

    inv-01: Initial Approval

    Target agent(s) will be approved when ALL of the following are met:

    Initial Approval Root: Initial approval requires meeting one of continuation criteria OR the specified new-use criteria, plus additional conditions.

    See children

    Entry path

    • Continuation of therapy: Member has been treated with the requested agent (starting on samples is not approvable) within the past 90 days; OR prescriber states treated with the requested agent within the past 90 days AND member is at risk if therapy is changed.

      [[chunk 4]]

    • New initiation for severe eosinophilic asthma

      • Phenotype confirmation: Baseline (prior to therapy) blood eosinophil count ≥150 cells/µL OR FeNO ≥20 ppb while on high‑dose inhaled corticosteroids or daily oral corticosteroids OR sputum eosinophils ≥2% while on high‑dose inhaled corticosteroids or daily oral corticosteroids OR systemic corticosteroid dependence.

        [[chunk 5]]

      • Evidence of uncontrolled asthma or prior biologic use: Two or more systemic corticosteroid bursts in the past 12 months OR one or more serious exacerbation (hospitalization, mechanical ventilation, or ER/urgent care) in the past 12 months OR asthma that worsens when corticosteroids are tapered OR baseline FEV1 <80% predicted OR medication history showing use of an FDA‑labeled or compendia‑supported biologic for asthma within the past 12 months OR the member has another FDA‑labeled indication for the requested agent and route of administration.

        [[chunk 5]]

    Additional required conditions: Member must meet baseline controller therapy and adherence requirements (e.g., treated with a maximally tolerated inhaled corticosteroid for ≥3 months with adherence for 90 days within the past 120 days, plus appropriate concurrent controller agents as specified), prescriber is a specialist or has consulted a specialist, member will NOT use the requested agent with another immunomodulatory agent unless prescribing information permits and clinical support for combination therapy is provided, and member does NOT have any FDA‑labeled contraindications to the requested agent.

    [[chunks 7,8]]

    inv-02: Renewal Criteria

    Target Agent(s) will be approved when ALL of the following are met:

    Renewal Root: Member was previously approved through the plan's prior authorization process; member has had clinical benefit on the requested agent; if severe eosinophilic asthma, member treated within the past 90 days and compliant with asthma control therapy; prescriber is a specialist or has consulted one; member will NOT be using the requested agent in combination with another immunomodulatory agent unless prescribing information does not limit combination use AND there is supporting evidence for combination therapy; and member does NOT have any FDA‑labeled contraindications to the requested agent.

    [[chunk 9]]

    The policy lists a broad set of immunomodulatory agents that are contraindicated as concomitant therapy with reslizumab (Cinqair). Providers must not prescribe Cinqair in combination with any agent on this list unless the plan’s continuation/combination criteria are specifically met (see renewal criteria). Examples from the policy include TNF inhibitors, IL‑4/IL‑13 and other biologics (e.g., Adalimumab, Nucala (mepolizumab), Fasenra (benralizumab), Dupixent (dupilumab), Omalizumab, and many others) and a long roster of branded immunomodulators and small‑molecule JAK inhibitors.

    If combination use is proposed, the renewal criteria require BOTH that the prescribing information for the requested agent does not limit use with another immunomodulator and that clinical evidence supporting combination therapy (clinical trials, phase III studies, or guideline references) is submitted. Absent that documentation, requests proposing concomitant therapy with listed agents are not supported.

    Medicare rules may supersede or add requirements for Part B members. The policy instructs providers to follow the Medicare Benefit Policy Manual (Pub. 100‑2, Chapter 15 §50) and to check for applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), or Local Coverage Articles (LCAs). Use the CMS coverage database to verify any Medicare requirements before billing or approving therapy for Medicare members.

    Where an LCD/NCD/LCA exists, those determinations must be followed in addition to the policy’s clinical criteria; the plan may apply additional indications at its discretion.

    Requests that do not meet the policy’s initial or renewal criteria will be considered not medically necessary. Common denial rationales include failure to meet phenotype or uncontrolled disease criteria (e.g., missing biomarker confirmation such as baseline blood eosinophils ≥150 cells/µL or required exacerbation history), lack of documented clinical benefit on renewal, or use that conflicts with the listed contraindicated concomitant immunomodulators.

    Additional denial triggers include absence of required documentation (prior biologic trials, adherence to controller therapy, specialist involvement), failure to obtain required prior authorization, and any FDA‑labeled contraindication to the requested agent.

    Billing, Codes, and Quantity Limits

    HCPCSHCPCSCovered
    J2786Injection, reslizumab, 1 mg; 1 billable unit = 1 mg
    NDCNDC
    59310-0610-xxCinqair 100 mg/10 mL single-use vial NDC
    Covered ICD-10 Diagnosis CodesICD-10Covered
    J45.50Severe persistent asthma, uncomplicated
    J82.81Chronic eosinophilic pneumonia
    J82.82Acute eosinophilic pneumonia
    J82.83Eosinophilic asthma
    J82.89Other pulmonary eosinophilia, not elsewhere classified
    Medicare Part B Covered Diagnosis CodesICD-10
    No codes listed
    Dosing limits and biomarker thresholds
    Maximum HCPCS billing units400 billable units every 4 weeks
    Baseline blood eosinophil threshold≥150 cells/microliter (prior to therapy)
    Alternative biomarker thresholdsFeNO ≥20 ppb on high-dose ICS or daily oral corticosteroids; sputum eosinophils ≥2% on high-dose ICS or daily oral corticosteroids

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior authorization validity: 12 months

    Initial and renewal prior authorizations for Cinqair (reslizumab) are issued for 12 months (365 days).

    Prior Authorization

    Prior authorization recommended — use plan PA process

    Prior authorization is considered appropriate for this drug based on the indication and cost; providers must use the plan's prior authorization process to request coverage.

    Step Therapy

    Required trial of other anti‑IL‑5 agents (benralizumab or mepolizumab)

    For new initiation in severe eosinophilic asthma, the member must have had a prior trial with documented failure, intolerance, or contraindication to benralizumab (Fasenra) or mepolizumab (Nucala).

    Drug Background and Indications

    Cinqair (reslizumab) is an intravenous monoclonal antibody targeting interleukin‑5 (anti‑IL‑5) used to treat severe eosinophilic asthma. The policy frames Cinqair as a specialist‑managed biologic requiring documentation of phenotype (blood eosinophils, FeNO, or sputum eosinophils), evidence of uncontrolled disease on controller therapy or prior biologic use, and prescriber specialty involvement.

    Dosing and administration expectations (e.g., weight‑based IV dosing at 3 mg/kg every 4 weeks per product labeling) and billing details are included elsewhere in the policy; prior authorization and ongoing documentation of clinical benefit are required to continue therapy.

    Key Definitions and Diagnostic Thresholds

    Severe eosinophilic asthma — phenotype & qualifying criteria
    Definition (phenotype)Severe eosinophilic asthma: asthma phenotype with supportive biomarkers — baseline blood eosinophils ≥150 cells/μl OR FeNO ≥20 ppb on high-dose ICS or daily oral corticosteroids OR sputum eosinophils ≥2% on high-dose ICS or daily oral corticosteroids OR systemic corticosteroid dependence.
    Clinical evidence of uncontrolled diseaseTwo or more systemic steroid bursts in past 12 months OR one or more serious exacerbation (hospitalization, mechanical ventilation, ER/urgent care) in past 12 months OR worsening when corticosteroids tapered OR baseline FEV1 <80% predicted.
    Prior biologic useMedication history showing use of an FDA-labeled or compendia-supported biologic for asthma within past 12 months counts toward qualifying evidence.
    Covered diagnosis codes — qualifying conditions
    Covered diagnosis (ICD-10)J45.50 — Severe persistent asthma, uncomplicated
    Policy Summary
    PayerViva Health
    PolicyCinqair (reslizumab) IV — coverage and prior authorization criteria
    Policy CodePolicy IC-P0273
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization; initial and renewals are valid for 12 months.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling, Codes, and Quantity LimitsPrior Authorization, Documentation, and Provider RequirementsDrug Background and IndicationsKey Definitions and Diagnostic Thresholds
    Step Therapy

    Step therapy — no explicit rules listed

    This policy does not list any additional explicit step therapy rules in the step therapy section.

    Documentation Required

    Required clinical documentation to support PA

    Submit documentation that supports prior biologic use and the eosinophilic phenotype and disease severity: baseline blood eosinophil count, FeNO or sputum eosinophils (as specified), evidence of systemic corticosteroid dependence, and history of exacerbations or FEV1 results.

    • Baseline blood eosinophil count ≥150 cells/microliter, or FeNO ≥20 ppb on high‑dose ICS or daily oral corticosteroids, or sputum eosinophils ≥2% on high‑dose ICS or daily oral corticosteroids, or systemic corticosteroid dependence (cite: baseline phenotype).
    • Evidence of uncontrolled asthma: two or more systemic steroid bursts in past 12 months, one or more serious exacerbation (hospitalization, mechanical ventilation, ER/urgent care) in past 12 months, worsening when corticosteroids tapered, or baseline FEV1 <80% predicted.
    • Medication history showing prior use of an FDA‑labeled or compendia‑supported biologic for asthma within the past 12 months, if applicable.
    • Documentation of adherence to maximally tolerated inhaled/controller therapies for required durations (e.g., ≥3 months ICS with 90 days adherence within past 120 days) and specialist involvement.
    Documentation Required

    Diagnosis code documentation — use listed ICD‑10 codes

    Include one of the listed ICD‑10 diagnosis codes with the request to support medical necessity for coverage.

    • Acceptable diagnosis codes include J45.50, J82.81, J82.82, J82.83, J82.89.
    Denial Risk

    Denial triggers — unmet criteria or missing documentation

    Requests that do not meet the initial or renewal criteria — including lack of required biomarker or clinical documentation, absence of documented clinical benefit on renewal, or noncompliance with required therapies — may be denied.

    Denial Risk

    Prior authorization risk — PA may be required; lack of PA can lead to denial

    Because the indication and drug cost were identified in the NQTL checklist, prior authorization may be applied; failure to obtain required prior authorization can result in denial of the request.

    Related covered eosinophilic diagnosesJ82.83 — Eosinophilic asthma; J82.81 — Chronic eosinophilic pneumonia
    Other covered pulmonary eosinophilia codesJ82.82 — Acute eosinophilic pneumonia; J82.89 — Other pulmonary eosinophilia, not elsewhere classified